XML 13 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Operating activities:    
Net loss $ (54,786) $ (73,864)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 1,075 1,072
Accretion of discount on available-for-sale securities (2,932) (1,695)
Stock-based compensation 9,602 9,267
Reduction in the carrying amount of right-of-use assets 627 538
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets (1,126) 818
Accounts payable (1,457) (152)
Accrued liabilities 194 (4,495)
Operating lease liabilities (1,152) (844)
Other current liabilities (21) (19)
Net cash used in operating activities (49,976) (69,374)
Investing activities:    
Purchases of property and equipment   (167)
Purchases of available-for-sale securities (266,183) (69,875)
Proceeds from maturities of available-for-sale securities 92,300 95,090
Net cash (used in) provided by investing activities (173,883) 25,048
Financing activities:    
Proceeds from the exercise of common stock options 388 111
Proceeds from Employee Stock Purchase Plan purchases 215 345
Proceeds from the issuance of common stock, including related party of zero and $17,995 for the six months ended June 30, 2024 and 2023, respectively 39,737 17,995
Proceeds from the issuance of common stock and pre-funded warrants, net of commissions 117,500  
Payment of financing costs (1,776) (525)
Net cash provided by financing activities 156,064 17,926
Decrease in cash, cash equivalents and restricted cash (67,795) (26,400)
Effect of exchange rate changes on cash, cash equivalents and restricted cash (11) (6)
Cash, cash equivalents and restricted cash    
Beginning of period 226,142 141,052
End of period 158,336 114,646
Supplemental disclosure of cash flow information:    
Cash paid for amounts included in the measurement of lease liability 2,432 $ 2,350
Non-cash investing and financing activities:    
Deferred offering costs included in accounts payable and accrued liabilities $ 320